Plain-English translation of NCT07928167 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a special type of radiation therapy called stereotactic radiation to a combination of two medications— and —can help people with advanced kidney cancer that has spread to other parts of the body. These two medications work together to help your immune system fight cancer, but some patients don't respond well enough to the medications alone. Researchers believe that adding targeted radiation to a few of your cancer spots might help the medications work better overall.
About one in five people taking this medication combination don't see their cancer shrink enough—it stays stable instead. Earlier research suggested that adding radiation to even one cancer spot improved outcomes, so researchers want to test whether treating up to three spots with radiation, combined with the ongoing medication, can help more patients respond to treatment.
You likely qualify if…
You likely don't qualify if…
All participants start with 12 weeks of the two medications together, then have scans to see how their cancer responds. If your cancer stays stable (doesn't shrink, but doesn't grow), you'll be randomly assigned to either continue the medications alone or add targeted radiation therapy to up to three of your cancer spots. You'll have regular scans every 12 weeks to check how the treatment is working. The study will track how many patients see their cancer shrink over time and how you tolerate the treatments.
AI-generated summary from trial data · Nov 11, 2026 · Not medical advice
Russia